Alkon said, "There is a long line of trials, all going after amyloid in different ways, that never have worked. What we're trying to say is, look at the elephant in the room. The elephant in the room is look at the loss of wiring in the brain."
Thanks, NTRP is under radar now. With good scientific target and drug, we have much better chance than any other competitors to succeed in fighting against one of the most difficult diseases.
Market Data 
Markets 
AI
